相关实验视频
Updated: Jun 21, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.4K
功能网络中断介于阿尔茨海默病中的传播,导致阿尔茨海默病的传播
1School of Medicine, Iran University of Medical Sciences, Tehran 441265421414, Iran.
Brain communications
|July 9, 2024
概括
阿尔茨海默病涉及到大脑断开连接. 这项研究表明,扩散会破坏局部大脑连接,独立于粉样β,影响大脑区域之间的通信.
科学领域:
- 神经科学是一个神经科学.
- 神经病理学神经病理学
- 神经成像是一种神经成像.
背景情况:
- 阿尔茨海默病是一种脱节综合征,其特征是由于粉样β斑块和团结而导致的神经衰竭.
- 聚合物的"子样"扩散被暗示,但其对突触功能和区域通信的局部影响仍然不清楚.
研究的目的:
- 研究聚合物如何通过功能性大脑连接传播,在本地影响功能性连接.
- 确定TAU传播与阿尔茨海默氏病中的功能断开之间的关系.
主要方法:
- 利用静止状态的功能性MRI连接体来模拟tau通过功能连接传播.
- 分析了来自阿尔茨海默氏病神经成像计划的211名参与者的成像数据 (117名粉样蛋白-beta阴性,94名粉样蛋白-beta阳性).
- 使用功能性MRI数据评估tau扩散对功能连接的影响.
主要成果:
- 较低的功能连接到tau中心与tau传播相关,观察到粉样β阴性和阳性个体.
- 在tau中心的粉样β-PET部分调解了tau传播和功能连接性之间的关联.
- 通过连接传播的在局部上与功能连接的破坏有关,独立于粉样β病理.
结论:
- 的传播有助于大脑内部的局部功能断开,影响区域之间的通信.
- 基于tau扩散和功能断开的定义组提供了对易感性或弹性的定量见解.
- 粉样蛋白-β,其他共同病理和APOE ε4等位基因被确定为tau相关功能断开的脆弱性因素.
相关概念视频
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177

